Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00585390

Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia

Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Essential Fatty Acid Deficiency Replacement in Early Schizophrenia

Sponsor: University of Cincinnati

Conditions Fatty Acid Deficiency Schizophrenia

Interventions EPA fish oil concentrate; DHA fish oil concentrate Olive oil placebo Omega-3 Fatty Acids Placebo

Updated 6 times since 2017 Last updated: Aug 1, 2011 Started: Jan 31, 2008 Primary completion: Nov 30, 2009 Completion: Nov 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2/PHASE3 trial investigates Fatty Acid Deficiency and Schizophrenia and is currently completed. University of Cincinnati leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2_PHASE3

First recorded

Jan 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Cincinnati

Data source: University of Cincinnati

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cincinnati, United States